EVERSION Raises €2.3 Million in Seed II Round
EVERSION, a company focused on analyzing and addressing musculoskeletal pain through movement data and sensor insoles, has successfully raised €2.3 million in its latest Seed II funding round. The investment was led by family office Kammerer Holding and the Kreissparkasse Biberach Fund.
Understanding Musculoskeletal Pain
Founded in 2023 by Lucas Heitele and Maximilian Starkmann, EVERSION is tackling a prevalent issue in Germany: musculoskeletal conditions, which are the leading cause of sick leave. The company aims to identify the root causes of pain that often go undetected, focusing not just on symptom relief but on understanding and addressing the underlying issues.
EVERSION utilizes a combination of an app and sensor insoles to conduct gait analysis, which measures everyday movement and identifies improper foot loading that can affect the knees, hips, and back. The company's unique approach includes the use of 0° soles, which are tailored to an individual's movement patterns, providing personalized recommendations.
Leadership and Vision
Lucas Heitele, Co-Founder and CTO, remarked on the company's mission: "Musculoskeletal complaints are the most common reason for sick leave in Germany, and yet we almost always only treat the symptoms." He emphasized the importance of their individualized approach to tackling these issues.
Strategic Use of Funds
The newly acquired funds will primarily be used to enhance EVERSION's technology, enabling further development of their gait analysis system and sensor insoles. The company is focused on expanding its innovative approach to understanding and mitigating musculoskeletal complaints.
Conclusion
This funding round signifies a strong vote of confidence in EVERSION's mission and technology. As the company continues to develop its solutions, it aims to provide more effective ways to understand and alleviate musculoskeletal pain, moving beyond traditional methods that primarily address symptoms.